A Phase 2 trial reported that mezagitamab, an investigational antibody, significantly increased platelet counts in patients with immune thrombocytopenia (ITP). The study positions mezagitamab as a potential new option in a disease defined by immune-driven platelet destruction and bleeding risk. The update described durable hematologic responses tied to platelet count improvements, a core clinical endpoint in ITP development. Mezagitamab’s mechanism and trial readouts were framed around clinically meaningful platelet elevation. For hematology-focused biotech, the data add to the competitive field of immune modulation strategies aimed at improving response rates while reducing the burden of chronic disease management.